IL13RA2 and glioblastoma: An ongoing clinical trial (NCT02208362) focusing on CAR T-cell therapy targeting IL13Rα2 for glioblastoma has demonstrated regression of all intracranial and distant spinal tumors after treatment, with this response lasting for 7.5 months.